Clinical trialNCT06844383RecruitingPhase 2Interventional

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

SponsorProstate Cancer Clinical Trials ConsortiumEnrollment126Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate or darolutamide

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Alicia Morgans, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
Recruiting
Ucsd Moores Cancer Center
La Jolla, California, United States
Rana McKay, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting
Masonic Cancer Center
Minneapolis, Minnesota, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Steven Blinka, MD
Recruiting
University of Wisconsin Carbone Cancer Center-Madison
Madison, Wisconsin, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Talazoparib →Talazoparib with enzalutamide

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 May 2026
Primary completion: 31 Mar 2029
Completion: 31 Mar 2030
Last update posted: 21 Aug 2026
Registered enrollment: 126
Registry id: NCT06844383

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.